Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study

被引：0
|
作者：
Yuichiro Kikawa
Takeshi Kotake
Shigeru Tsuyuki
Yookija Kang
Sachiko Takahara
Yuri Fujimoto
Hiroyasu Yamashiro
Hiroshi Yoshibayashi
Masahiro Takada
Rie Yasuoka
Katsuhiko Nakatsukasa
Kazuhiko Yamagami
Hirofumi Suwa
Toshitaka Okuno
Ichiro Nakayama
Tatsushi Kato
Nobuko Ogura
Yoshio Moriguchi
Hiroshi Ishiguro
Tatsuo Kagimura
Tetsuya Taguchi
Tomoharu Sugie
Masakazu Toi
机构：
[1] Kansai Medical University,Department of Breast Surgery
[2] Kobe City Medical Center General Hospital,Department of Breast Surgery
[3] Kyoto University Graduate School of Medicine,Department of Breast Surgery
[4] Kansai Electric Power Hospital,Department of Breast Surgery
[5] Osaka Red Cross Hospital,Department of Breast Surgery
[6] Kitano Hospital,Department of Breast Surgery, Tazuke Kofukai Medical Research Institute
[7] Tenri Hospital,Department of Breast Surgery
[8] Wakayama Breast Clinic,Department of Endocrine and Breast Surgery
[9] Kyoto Prefectural University of Medicine,Department of Breast Surgery
[10] Shinko Hospital,Department of Breast Surgery
[11] Hyogo Prefectural Amagasaki General Medical Center,Department of Breast Surgery
[12] Kobe City Nishi-Kobe Medical Center,Department of Breast Surgery
[13] Kyoto Min-Iren Chuo Hospital,Department of Breast Surgery, Yamato Takada Municipal Hospital
[14] Yamatotakada-city,Department of Breast Surgery
[15] Kyoto City Hospital,Breast Oncology Service
[16] Saitama Medical University International Medical Center,Translational Research Center for Medical Innovation
[17] Foundation for Biomedical Research and Innovation at Kobe,undefined
来源：
Breast Cancer | 2022年 / 29卷
关键词：
Breast cancer; Metastasis; Eribulin; Chemotherapy sequence; Real world;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：796 / 807
页数：11
相关论文
共 22 条
  • [1] Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study
    Kikawa, Yuichiro
    Kotake, Takeshi
    Tsuyuki, Shigeru
    Kang, Yookija
    Takahara, Sachiko
    Fujimoto, Yuri
    Yamashiro, Hiroyasu
    Yoshibayashi, Hiroshi
    Takada, Masahiro
    Yasuoka, Rie
    Nakatsukasa, Katsuhiko
    Yamagami, Kazuhiko
    Suwa, Hirofumi
    Okuno, Toshitaka
    Nakayama, Ichiro
    Kato, Tatsushi
    Ogura, Nobuko
    Moriguchi, Yoshio
    Ishiguro, Hiroshi
    Kagimura, Tatsuo
    Taguchi, Tetsuya
    Sugie, Tomoharu
    Toi, Masakazu
    BREAST CANCER, 2022, 29 (05) : 796 - 807
  • [2] Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study
    Shogo Nakamoto
    Junichiro Watanabe
    Shoichiro Ohtani
    Satoshi Morita
    Masahiko Ikeda
    BMC Cancer, 22
  • [3] Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study
    Nakamoto, Shogo
    Watanabe, Junichiro
    Ohtani, Shoichiro
    Morita, Satoshi
    Ikeda, Masahiko
    BMC CANCER, 2022, 22 (01)
  • [4] Endocrine therapy or chemotherapy as first-line therapy in hormone receptorepositive HER2-negative metastatic breast cancer patients
    Jacquet, E.
    Lardy-Cleaud, A.
    Pistilli, B.
    Franck, S.
    Cottu, P.
    Delaloge, S.
    Debled, M.
    Vanlemmens, L.
    Leheurteur, M.
    Guizard, A. V.
    Laborde, L.
    Uwer, L.
    Jacot, W.
    Berchery, D.
    Desmoulins, I.
    Ferrero, J. M.
    Perrocheau, G.
    Courtinard, C.
    Brain, E.
    Chabaud, S.
    Robain, M.
    Bachelot, T.
    EUROPEAN JOURNAL OF CANCER, 2018, 95 : 93 - 101
  • [5] Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)
    Kenjiro Aogi
    Kenichi Watanabe
    Masahiro Kitada
    Takafumi Sangai
    Shoichiro Ohtani
    Tomoyuki Aruga
    Hidetoshi Kawaguchi
    Tomomi Fujisawa
    Shigeto Maeda
    Takashi Morimoto
    Nobuaki Sato
    Shintaro Takao
    Satoshi Morita
    Norikazu Masuda
    Masakazu Toi
    Shinji Ohno
    International Journal of Clinical Oncology, 2021, 26 : 1229 - 1236
  • [6] Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study
    Delaloge, S.
    Perol, D.
    Courtinard, C.
    Brain, E.
    Asselain, B.
    Bachelot, T.
    Debled, M.
    Dieras, V.
    Campone, M.
    Levy, C.
    Jacot, W.
    Lorgis, V.
    Veyret, C.
    Dalenc, F.
    Ferrero, J. M.
    Uwer, L.
    Kerbrat, P.
    Goncalves, A.
    Mouret-Reynier, M. A.
    Petit, T.
    Jouannaud, C.
    Vanlemmens, L.
    Chenuc, G.
    Guesmia, T.
    Robain, M.
    Cailliot, C.
    ANNALS OF ONCOLOGY, 2016, 27 (09) : 1725 - 1732
  • [7] First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study
    Hardy-Bessard, Anne-Claire
    Brocard, Fabien
    Clatot, Florian
    Lortholary, Alain
    You, Benoit
    Grenier, Julien
    Martin-Babau, Jerome
    Lucas, Brigitte
    Meunier, Jerome
    Ferrero, Jean-Marc
    Savoye, Aude-Marie
    Marti, Adina
    Despax, Raymond
    Moullet, Isabelle
    Emile, George
    BREAST, 2020, 54 : 256 - 263
  • [8] A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes
    Kosei Kimura
    Mitsuhiko Iwamoto
    Satoru Tanaka
    Daigo Yamamoto
    Katsuhide Yoshidome
    Hiroyuki Ogura
    Risa Terasawa
    Nobuki Matsunami
    Yuko Takahashi
    Toshikatsu Nitta
    Takashi Morimoto
    Hiroya Fujioka
    Kanako Kawaguchi
    Kazuhisa Uchiyama
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 923 - 933
  • [9] A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes
    Kimura, Kosei
    Iwamoto, Mitsuhiko
    Tanaka, Satoru
    Yamamoto, Daigo
    Yoshidome, Katsuhide
    Ogura, Hiroyuki
    Terasawa, Risa
    Matsunami, Nobuki
    Takahashi, Yuko
    Nitta, Toshikatsu
    Morimoto, Takashi
    Fujioka, Hiroya
    Kawaguchi, Kanako
    Uchiyama, Kazuhisa
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (05) : 923 - 933
  • [10] High reduction of circulating tumour cells in HER2-negative locally advanced or metastatic breast cancer (LAMBC) patients treated with eribulin as third line chemotherapy (ONSITE study)
    Manso Sanchez, L.
    Moreno Anton, F.
    Izarzugaza Peron, Y.
    Delgado Mingorance, I.
    Borrega Garcia, P.
    Echarri Gonzalez, M. J.
    Martinez Janez, N.
    Lopez Gonzalez, A.
    Olier Garate, C.
    Ballesteros Garcia, A.
    Chacon Lopez-Muniz, I.
    Ciruelos Gil, E. M.
    Garcia Saenz, J. A.
    Paz-Ares Rodriguez, L.
    CANCER RESEARCH, 2017, 77
123